“…Most studies are small case reports with inconsistent dosing regimens, intervals, and duration of treatment, and a variety of adjunctive therapies (Table I). In addition, the rates of complete response, partial response, stable disease, and disease progression have been highly inconsistent, ranging from no response or progression in 75% of patients 10 to a complete response of 96% of lesions 11. With such varied responses in outcome, and with a treatment option that appears to be associated with minimal morbidity, our purpose was to document the response of in‐transit metastases to intra‐lesional IL‐2 injection using a consistent regimen in a large series of consecutive patients.…”